Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/32183
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17776/20117 (88%)
造访人次 : 12153096      在线人数 : 219
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.cnu.edu.tw/handle/310902800/32183


    標題: Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer
    作者: Tian, Yu-Feng
    Wang, Hui-Ching
    Luo, Chi-Wen
    Hung, Wen-Chun
    Lin, Yu-Han
    Chen, Tzu-Yi
    Li, Chien-Feng
    Lin, Chen-Yi
    Pan, Mei-Ren
    貢獻者: Chi Mei Med Ctr, Dept Surg, Div Colorectal Surg
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med
    Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol
    Chang Gung Mem Hosp, Kaohsiung Med Ctr, Div Cardiol
    Natl Hlth Res Inst, Natl Inst Canc Res
    Chi Mei Med Ctr, Dept Pathol
    Natl Hlth Res Inst, Natl Inst Canc Res
    Southern Taiwan Univ Sci & Technol, Dept Biotechnol
    Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol
    關鍵字: EHMT2
    SKP2
    p27
    pancreatic cancer
    cell cycle
    日期: 2018
    上傳時間: 2019-11-15 15:44:06 (UTC+8)
    出版者: E-CENTURY PUBLISHING CORP
    摘要: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease, which is characterized by its high invasiveness, rapid progression, and profound resistance to therapy. Gemcitabine is the first-line treatment option for pancreatic cancer patients, but the overall survival is quite low. Therefore, it is an urgent issue to identify new molecules for improved therapies, with better efficacy and less toxicity. Our previous data indicated that Euchromatic histone-lysine N-methyltransferase 2 (EHMT2) functions as a therapeutic target to override GEM resistance and promote metastasis in the treatment of pancreatic cancer. Here, we screened a small-molecule library of 143 protein kinase inhibitors, to verify cytotoxicity of different inhibitors in EHMT2-depleted cells. We determined that the EHMT2 plays a promising modulating role for targeted PI3K/mTOR inhibition. Our data revealed that EHMT2 down-regulates p27 expression, and this contributes to tumor growth. The depletion of EHMT2, ectopic expression of methyltransferase-dead EHMT2, or treatment with an EHMT2 inhibitor decreases H3K9 methylation of p27 promoter and induces G1 arrest in PANC-1 pancreatic cancer cells. Consistent with these findings, in vivo tumor xenograft models, primary tumors, and the Oncomine database utilizing bioinformatics approaches, also show a negative correlation between EHMT2 and p27. We further demonstrated that low EHMT2 elevated BEZ235 sensitivity through up-regulation of p27 in PDAC cells; high levels of SKP2 decrease BEZ235 responsiveness in PDAC cells. Altogether, our results suggest the EHMT2-p27 axis as a potential marker to modulate cell response to dual PI3K/mTOR inhibition, which might provide a strategy in personalized therapeutics for PDAC patients.
    關聯: Minerva Anestesiologica, v.8, n.9, pp.1812-1822
    显示于类别:[保健營養系(所) ] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    ajcr0008-1812.pdf1642KbAdobe PDF60检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈